TrialMultiple sclerosis (Houndmills, Basingstoke, England)2018

Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.

Edward J Fox et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.